CBX

 Biosion submitted the IND application for BSI-992, a TROP2 ADC, on April 9th, 2024 in China. The TROP2 targeting antibody, discovered by Biosion, was licensed to OBI Pharma in 2021. OBI ADC Technology OBI Pharma (台灣浩鼎) owns the ex-China right of BSI-992/OBI-992 , with the US FDA clearing  an IND application for a Phase 1/2 Study in Jan 2024. The phase 1 trial in the US is estimated to be completed in 2025Q2. Besides OBI-992, OBI Pharma has also discovered a next-generation anti-TROP2 ADC, OBI-902, using the GlycOBI platform in various drug-antibody ratios (DAR). Furthermore, a BsADC targeting TROP2 and HER2 is currently in the preclinical stage. BSI-992/ OBI-992 OBI-992 is a TROP2-directed antibody-drug-conjugate (ADC) that carries a potent topoisomerase I inhibitor and uses a hydrophilic, enzyme-cleavable linker. Upon binding to TROP2 on the surface of cancer cells, OBI-992 is internalized into the cell and trafficked to lysosomes where the linker is cleaved by cathepsin B, releasing

 Alphamab Oncology has submitted the IND application for JSKN016, an anti-HER3xTROP2 ADC designed for the treatment of solid tumors in China. JSKN016 represents a potential first-in-class bispecific ADC, developed using the glycan-specific conjugation platform to target both HER3 and TROP2. No further details have been reported, and we will provide updates as they become available. Anti-TROP2 ADC, sacituzumab govitecan, has received approval for the treatment of breast cancer and urothelial cancer. Lung cancer may be the next targeting indication. Concurrently, anti-HER3 ADCs are widely investigated for their therapeutic potential in both lung cancer and breast cancer.